Introduction and Background
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that has attracted substantial attention within endocrinological and metabolic research over the past decade. Originally developed as a therapeutic agent for glycaemic regulation, semaglutide belongs to the incretin mimetic class of peptides and represents a significant advancement in GLP-1 analogue engineering (Knudsen and Lau, 2019). The native GLP-1 hormone, secreted by intestinal L-cells in response to nutrient ingestion, plays a central role in glucose homeostasis through stimulation of insulin secretion, suppression of glucagon release, and modulation of gastric emptying (Drucker, 2018).
The development of semaglutide arose from the need to overcome the inherent pharmacokinetic limitations of native GLP-1, which exhibits a plasma half-life of approximately two minutes due to rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and renal clearance. Through strategic molecular modifications, researchers at Novo Nordisk engineered semaglutide to achieve a markedly extended duration of action, enabling once-weekly subcutaneous administration. The structural basis for this prolonged half-life, and its downstream pharmacological consequences, have been extensively characterised in the literature (Lau et al., 2015).
Mechanism of Action
Semaglutide exerts its pharmacological effects primarily through high-affinity binding to the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor expressed in pancreatic beta cells, the gastrointestinal tract, the central nervous system, and the cardiovascular system (Drucker, 2018). Upon receptor engagement, semaglutide activates adenylyl cyclase via the stimulatory G-protein (Gαs), leading to intracellular cyclic adenosine monophosphate (cAMP) accumulation. This cascade potentiates glucose-dependent insulin secretion from pancreatic beta cells while simultaneously suppressing glucagon release from alpha cells, thereby providing a dual mechanism for glycaemic regulation that carries a reduced risk of hypoglycaemia compared with insulin secretagogues.
Beyond its pancreatic effects, GLP-1R activation in the central nervous system, particularly within the hypothalamic arcuate nucleus and the brainstem nucleus tractus solitarius, mediates appetite suppression and satiety signalling. Semaglutide has demonstrated the ability to cross the blood-brain barrier, and preclinical studies suggest direct neuronal GLP-1R engagement as a key contributor to its effects on energy intake (Drucker, 2018). Additionally, GLP-1R agonism delays gastric emptying through vagal afferent pathways, contributing to reduced postprandial glucose excursions and enhanced satiety.
Structural Modifications
The molecular architecture of semaglutide is based on the human GLP-1(7-37) sequence with three critical modifications that confer its extended pharmacokinetic profile. First, an amino acid substitution at position 8 (Ala8→Aib) confers resistance to DPP-4-mediated proteolysis. Second, a substitution at position 34 (Lys34→Arg) prevents fatty acid acylation at an unintended site. Third, and most critically, a C-18 fatty diacid moiety is conjugated to Lys26 via a linker, facilitating high-affinity non-covalent binding to serum albumin. This albumin association substantially reduces renal clearance and shields the peptide from enzymatic degradation, resulting in a plasma half-life of approximately 165 hours in humans (Lau et al., 2015).
Key Clinical Research Findings
Glycaemic Regulation Studies
The SUSTAIN clinical trial programme, comprising a series of phase 3 and 3b studies, systematically evaluated the efficacy and safety profile of subcutaneous semaglutide in populations with type 2 diabetes mellitus. In the pivotal SUSTAIN 1 trial, once-weekly semaglutide at doses of 0.5 mg and 1.0 mg demonstrated statistically significant reductions in glycated haemoglobin (HbA1c) compared with placebo over 30 weeks, with mean reductions of 1.45% and 1.55% respectively (Sorli et al., 2017). These findings established semaglutide as one of the most potent GLP-1 receptor agonists investigated to date in terms of glycaemic lowering efficacy.
Subsequent head-to-head comparisons within the SUSTAIN programme further delineated the relative efficacy of semaglutide. SUSTAIN 7, a randomised open-label trial comparing semaglutide with dulaglutide, reported superior HbA1c reductions and greater body mass reduction in the semaglutide cohorts at both dose levels (Pratley et al., 2018). These comparative data positioned semaglutide as a leading agent within its pharmacological class.
Cardiovascular Outcomes
Cardiovascular safety and potential benefit have been areas of intense investigation for GLP-1 receptor agonists following landmark findings with liraglutide in the LEADER trial (Marso et al., 2016). The SUSTAIN-6 trial, a dedicated cardiovascular outcomes study, randomised 3,297 participants with type 2 diabetes and high cardiovascular risk to semaglutide or placebo. Over a median follow-up of 2.1 years, semaglutide was associated with a 26% reduction in the primary composite endpoint of major adverse cardiovascular events (MACE), comprising cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke (hazard ratio 0.74; 95% CI 0.58-0.95) (Marso et al., 2016). This reduction was driven predominantly by a significant decrease in non-fatal stroke incidence.
The PIONEER 6 trial subsequently assessed cardiovascular safety of oral semaglutide, confirming non-inferiority to placebo for MACE in a population with established cardiovascular disease or cardiovascular risk factors (Husain et al., 2019). While not powered for superiority, point estimates favoured oral semaglutide for the primary composite endpoint, suggesting a consistent cardiovascular signal across formulations.
Body Mass Research
The STEP (Semaglutide Treatment Effect in People with Obesity) clinical programme examined higher-dose semaglutide (2.4 mg weekly) in populations with overweight or obesity, with or without type 2 diabetes. The STEP 1 trial, a landmark double-blind study enrolling 1,961 adults, reported a mean body mass reduction of 14.9% with semaglutide compared with 2.4% with placebo over 68 weeks. Notably, one-third of participants in the semaglutide group achieved a reduction of 20% or greater (Wilding et al., 2021). These results represented a significant advance in pharmacological approaches to obesity research.
The STEP 4 trial further explored the effects of treatment continuation versus discontinuation. Participants who were switched from semaglutide to placebo after an initial 20-week run-in period experienced a regain in body mass, while those continuing semaglutide achieved further reductions, underscoring the requirement for sustained GLP-1R agonism to maintain treatment-associated effects (Rubino et al., 2021).
Pharmacokinetics
The pharmacokinetic profile of semaglutide is characterised by slow absorption from the subcutaneous injection site, with peak plasma concentrations (Tmax) achieved at approximately 24 to 72 hours post-administration. The terminal elimination half-life of approximately 165 hours (roughly seven days) supports once-weekly dosing, with steady-state concentrations attained after four to five weekly administrations (Lau et al., 2015). Semaglutide demonstrates linear pharmacokinetics across the investigated dose range, with an absolute bioavailability of approximately 89% following subcutaneous injection.
The oral formulation of semaglutide, co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), represents a notable pharmaceutical achievement. SNAC facilitates transcellular absorption across the gastric epithelium by transiently increasing local pH and promoting peptide solubility, yielding an oral bioavailability of approximately 0.4 to 1% (Husain et al., 2019). Despite this low absolute bioavailability, the oral formulation achieves therapeutically relevant plasma concentrations owing to the high potency of semaglutide at the GLP-1 receptor.
Semaglutide is primarily eliminated through proteolytic degradation and beta-oxidation of the fatty acid side chain. Renal and hepatic impairment studies have demonstrated that no dose adjustment is required across varying degrees of organ function compromise, consistent with the albumin-mediated distribution and proteolytic clearance mechanisms that do not depend on single-organ elimination pathways (Knudsen and Lau, 2019).
Current Research Directions
Non-Alcoholic Steatohepatitis (NASH)
Emerging research has extended the investigation of semaglutide into hepatic steatosis and non-alcoholic steatohepatitis (NASH). A phase 2 placebo-controlled trial demonstrated that daily subcutaneous semaglutide at a dose of 0.4 mg achieved histological resolution of steatohepatitis without worsening of fibrosis in a significantly greater proportion of participants compared with placebo (59% versus 17%) (Newsome et al., 2021). These findings have prompted further investigation in phase 3 trials and suggest that GLP-1R agonism may exert direct or indirect hepatoprotective effects beyond those attributable to improvements in body composition and insulin sensitivity.
Neurodegenerative Research
The expression of GLP-1 receptors in the central nervous system has stimulated research into potential neuroprotective properties of GLP-1 receptor agonists, including semaglutide. Preclinical models have demonstrated that GLP-1R activation reduces neuroinflammation, attenuates oxidative stress, and promotes neuronal survival in models of neurodegenerative pathology (Drucker, 2018). Clinical trials evaluating semaglutide in early-stage Alzheimer's disease are currently underway, and this represents one of the most active areas of translational research for GLP-1 receptor agonists.
Cardiovascular Risk Reduction
Building upon the cardiovascular findings from SUSTAIN-6 and PIONEER 6, large-scale cardiovascular outcomes trials are investigating the effects of semaglutide in broader populations, including those without diabetes but with established atherosclerotic disease. The SELECT trial and related studies aim to determine whether the cardiovascular benefits observed with semaglutide extend beyond glycaemic modulation to encompass direct anti-atherosclerotic, anti-inflammatory, or endothelial-protective mechanisms (Marso et al., 2016). These investigations may fundamentally reshape the understanding of GLP-1R agonism as a broader cardiometabolic intervention rather than solely a glucose-lowering strategy.
Combination Approaches
A rapidly advancing frontier in incretin-based research involves the development of multi-receptor agonists that combine GLP-1 receptor activation with agonism at the glucose- dependent insulinotropic polypeptide (GIP) receptor and/or the glucagon receptor. These dual and triple agonists aim to augment the metabolic effects observed with selective GLP-1R agonists such as semaglutide. The mechanistic rationale for polypharmacological receptor engagement, and the extent to which synergistic signalling may enhance or alter the therapeutic profile relative to selective GLP-1R agonism, remain active areas of investigation (Knudsen and Lau, 2019).